{
  "docId": "019de073-ec7b-760b-b9a4-60ceb97e90d9",
  "docSlug": "fef1528177829f37cded553f72a56b72",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 44 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 44,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a list-based structure to highlight key R&D milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ec7b-760b-b9a4-60ceb97e90d9/6",
  "deckHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9",
  "deckJsonHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9.json",
  "deckAnchorHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.6,
        "x": 0.367,
        "y": 0.425
      },
      "kind": "list",
      "text": "19 regulatory approvals in major markets, including: Ultomiris (EU, JP) generalised myasthenia gravis (CHAMPION-MG); Enhertu (US) HER2-low breast cancer (DESTINY-Breast04); Enhertu (US) HER2m NSCLC (DESTINY-Lung02); Tezspire (EU, JP) severe asthma (NAVIGATOR); Imfinzi (US) locally advanced or metastatic BTC (TOPAZ-1); Imjudo + Imfinzi (US) unresectable HCC (HIMALAYA); Beyfortus (EU) prevention of LRTI caused by RSV (MELODY/MEDLEY)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17e0085b-8a04-4f44-875a-37d304cba8fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.367,
        "y": 0.225
      },
      "kind": "list",
      "text": "Phase III data readouts: danicopan (ALXN2040) ALPHA PNH with clinically significant EVH; capivasertib CAPItello-291 HR-positive advanced breast cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "751fb212-fa24-4156-b23e-48782bbd0e44",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.58,
        "x": 0.387,
        "y": 0.925
      },
      "kind": "source-note",
      "text": "PNH = paroxysmal nocturnal haemoglobinuria; EVH = extravascular haemolysis; HR-positive = hormone receptor-positive; HER2-low = human epidermal growth factor receptor 2-low; HER2m = human epidermal growth factor receptor 2-mutated; NSCLC = non-small cell lung cancer; BTC = biliary tract cancer; HCC = hepatocellular carcinoma; LRTI = lower respiratory tract infection; RSV = respiratory syncytial virus. Collaboration partners: Daiichi Sankyo (Enhertu), Sanofi (Beyfortus), Amgen (Tezspire).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f11d82e2-78f3-4631-bb57-fabb3cf1110b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.034,
        "w": 0.553,
        "x": 0.367,
        "y": 0.138
      },
      "kind": "title",
      "text": "Continued strong pipeline progress since H1 2022",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6798b726-4da9-4eff-a1ff-b25e6f3e4815",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.042,
        "w": 0.315,
        "x": 0.367,
        "y": 0.028
      },
      "kind": "title",
      "text": "Science-led innovation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ff53fca-b267-4a21-bbcc-00f7eb231f39",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 6,
      "beatId": "4b3ef097-62f5-431e-83c6-c5b8bb7d6637",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "Slides 6-8 highlight the growth outlook and science-led innovation.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 7,
      "from": 6,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "35ca0bdd-15a3-425d-9a3c-784ee90d20a2",
      "evidence": "Slides 6-7 discuss science-led innovation and growth outlook.",
      "position": 1,
      "objective": "Emphasizing science-led innovation",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}